Trials / Completed
CompletedNCT01379677
Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison
Diagnosis of Coronary Artery Disease With Rubidium-82 PET and Technetium-99m-MIBI SPET: A Head to Head Comparison, Versus Coronary CT Angiography
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Advanced Accelerator Applications · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to compare myocardial perfusion imaging using Rubidium-82 PET with Tc-99m-MIBI SPET, in the evaluation of significant Coronary Artery Disease (CAD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rubidium-82 | Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use |
| DRUG | Sestamibi. reconstitution with sodium pertechnetate (99mTc) | Maximum dose allowed per injection: 1000 MBq Intravenous Use |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2011-06-23
- Last updated
- 2014-05-14
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01379677. Inclusion in this directory is not an endorsement.